First Treatment for Demodex Blepharitis Wins FDA Approval
The FDA approved lotilaner ophthalmic solution 0.25% (Xdemvy) as the first…
Browsing Tag
Blepharitis
FDA Approves XDEMVY™ (lotilaner ophthalmic solution) 0.25% for the treatment of…
XDEMVY is the first and only approved therapeutic for Demodex blepharitis, a highly prevalent eyelid disease that impacts approximately 25 million eye care patients in the U.S. XDEMVY…
LianBio Doses First Patient in Registrational Phase 3 LIBRA Trial of TP-03 in Chinese…
• LIBRA trial designed to support registration in China• Topline results expected in the fourth quarter of 2023 SHANGHAI and PRINCETON, N.J., Nov. 01, 2022 (GLOBE NEWSWIRE) --…
Tarsus to Present Saturn-2 Pivotal Phase 3 Trial Data and Saturn-1 Extension Study…
Positive data to be presented at WCC VIII and AAO 2022 conferences in Chicago Tarsus recently submitted NDA to the FDA for TP-03 IRVINE, Calif., Sept. 27, 2022 (GLOBE NEWSWIRE) --…
Tarsus Presents Results of Two Studies Highlighting Demodex Blepharitis Patient…
IRVINE, Calif., April 26, 2022 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to focus on unmet needs and apply proven science and new technology to…
Tarsus Pharmaceuticals, Inc. Announces Positive Results of Saturn-1 Pivotal Trial…
Saturn-1 Phase 2b/3 trial met all primary and secondary endpoints, and demonstrated significant, clinically meaningful outcomes with no serious treatment-related adverse events and no…
Tarsus Pharmaceuticals, Inc. Schedules Conference Call and Webcast to Announce…
IRVINE, Calif., June 18, 2021 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), a late clinical-stage biopharmaceutical company whose mission is to focus on unmet needs and…